Willingness to receive medication for opioid use disorder (MOUD): A longitudinal analysis of social network support

接受阿片类药物使用障碍药物治疗(MOUD)的意愿:一项基于社会网络支持的纵向分析

阅读:2

Abstract

BACKGROUND: Medications for opioid use disorder (MOUD, i.e., buprenorphine, methadone, naltrexone) save lives, but many individuals are unwilling to receive MOUD treatment. Few longitudinal studies have examined whether social network support for MOUD is related to willingness to receive MOUD. METHODS: Egocentric network data were collected from 393 adults with OUD who were incarcerated in 14 Kentucky prisons; follow-up data were collected about six months post-release. For each named alter, participants (egos) reported on perceived alters' support for buprenorphine, methadone, and naltrexone at baseline and follow-up; baseline network scores were averaged into a network support for MOUD score and a change score from baseline to follow-up was calculated. Multiple imputation by chained equations addressed missing data. A multivariate linear regression model of willingness to receive MOUD at follow-up was estimated that included baseline network support for MOUD, change in network support, baseline willingness to receive MOUD, lifetime history of MOUD, and demographics. RESULTS: Baseline network support for MOUD was positively associated with willingness to receive MOUD at follow-up (b=0.190, 95 % CI: 0.072-0.308, p < .01). Increase in network support for MOUD over time was also positively associated with willingness to receive MOUD at follow-up (b=0.210, 95 % CI: 0.102-0.319, p < .001). CONCLUSION: Social network support for MOUD, both the initial level and change over time, was associated with participants' willingness to receive MOUD. These findings suggest that intervention development focused on increasing social network support may have utility in increasing uptake of MOUD.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。